theraflu 500 mg/100 mg/6,1 mg trde kapsule
glaxosmithkline consumer healthcare (uk) trading limited - fenilefrin; gvaifenezin; paracetamol - kapsula, trda - fenilefrin 5 mg / 1 kapsula gvaifenezin100 mg / 1 kapsula paracetamol500 mg / 1 kapsula; gvaifenezin 100 mg / 1 kapsula paracetamol500 mg / 1 kapsula; paracetamol 500 mg / 1 kapsula - paracetamol, kombinacije brez psiholeptikov
theraflu 500 mg/100 mg/6,1 mg trde kapsule
glaxosmithkline consumer healthcare (uk) trading limited - fenilefrin, gvaifenezin, paracetamol - kapsula, trda - fenilefrin 5 mg / 1 kapsula; gvaifenezin 100 mg / 1 kapsula; paracetamol 500 mg / 1 kapsula - paracetamol, kombinacije brez psiholeptikov
theraflu 1000 mg/200 mg/12,2 mg prašek za peroralno raztopino
glaxosmithkline consumer healthcare (uk) trading limited - fenilefrin; gvaifenezin; paracetamol - prašek za peroralno raztopino - fenilefrin 10 mg / 1 g gvaifenezin200 mg / 1 g paracetamol1000 mg / 1 g; gvaifenezin 200 mg / 1 g paracetamol1000 mg / 1 g; paracetamol 1000 mg / 1 g - paracetamol, kombinacije brez psiholeptikov
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - sredstva za dermatitis, razen kortikosteroidov - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
repose
le vet beheer -
kuterid 0,5 mg/g mazilo
lek d.d. - betametazon - mazilo - betametazon 0,5 mg / 1 g - betametazon
kuterid 0,5 mg/g mazilo
lek d.d. - betametazon - mazilo - betametazon 0,5 mg / 1 g - betametazon
hidrasec 100 mg trde kapsule
bioprojet europe ltd. - racekadotril - kapsula, trda - racekadotril 100 mg / 1 kapsula - racekadotril
hidrasec 100 mg trde kapsule
bioprojet europe ltd. - racekadotril - kapsula, trda - racekadotril 100 mg / 1 kapsula - racekadotril
hidrasec za otroke 30 mg zrnca za peroralno suspenzijo
bioprojet europe ltd. - racekadotril - zrnca za peroralno suspenzijo - racekadotril 30 mg / 1 vrečica - racekadotril